IGF-1 LR3

—

evidence score

peptide

Research Only

Evidence Level D

Long R3 IGF-1insulin-like growth factor-1 long arginine 3

IGF-1 LR3 is a modified long-acting analog of IGF-1 engineered for reduced IGFBP binding and prolonged activity relative to native IGF-1. It is widely sold in gray/research channels for bodybuilding and experimental use, but lacks robust controlled human safety/efficacy data.

Safety & legal caution

Educational database only — not medical or legal advice.

Safety

No high-quality clinical evidence supports routine non-medical use.
Potential hypoglycemia, edema, and theoretical tumor-promoting risk from chronic mitogenic signaling.
Product purity/counterfeit risk is substantial in non-pharmacy supply chains.

Legal / compliance

Typically sold as research material; not approved for therapeutic use in most jurisdictions.
Likely prohibited by anti-doping organizations.

Current literature links

IGF system in muscle hypertrophy and regeneration(2014)WADA prohibited list (growth factors)(2025)

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal trials

Last Sync

Not synced yet

Last Reviewed

Not reviewed yet

Dosing

Typical

40 mcg

20 mcgRange100 mcg

FrequencyOnce daily (research protocols vary)

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~20–30 hours (reported, context-dependent)

OnsetHours for metabolic signaling; weeks for body-composition claims

Duration~1 day biological activity window

Routes

subcutaneous

intramuscular

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(24%)—

Quality(24%)—

Sample Size(12%)—

Consistency(14%)—

Replication(8%)—

Recency(18%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

IGF-1 LR3 is currently categorized as a peptide compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

IGF1R activation with prolonged exposure due to reduced binding to IGF-binding proteins

Practical Context

Strongest current signals

No indexed study summaries yet.